Highlights
KLSE: GENM (4715)       GENTING MALAYSIA BHD MAIN : Consumer
Last Price Today's Change   Day's Range   Trading Volume
2.51   +0.06 (2.45%)  2.47 - 2.53  11,680,600
Analyze this stock with MQ Trader system

Financials


Market Cap: 14,904 Million

Market Cap 14,904 Million
NOSH 5,938 Million

Latest Audited Result:  31-Dec-2019

Latest Audited Result: 31-Dec-2019
Announcement Date 08-Apr-2020
Next Audited Result: 31-Dec-2020
Est. Ann. Date: 08-Apr-2021
Est. Ann. Due Date: 29-Jun-2021

Latest Quarter:  30-Sep-2020 [#3]

Latest Quarter: 30-Sep-2020 [#3]
Announcement Date 26-Nov-2020
Next Quarter: 31-Dec-2020
Est. Ann. Date: 27-Feb-2021
Est. Ann. Due Date: 01-Mar-2021
QoQ | YoY   21.74%  |    -271.51%

Annual (Unaudited) ( EPS: 23.50, P/E: 10.68 )

Revenue | NP to SH 10,406,938  |  1,395,353
RPS | P/RPS 175.26 Cent  |  1.43
EPS | P/E | EY 23.50 Cent  |  10.68  |  9.36%
DPS | DY | Payout % 19.04 Cent  |  7.59%  |  81.04%
NAPS | P/NAPS 3.11  |  0.81
YoY   7,223.51%
NP Margin | ROE 12.80%  |  7.55%
F.Y. | Ann. Date 31-Dec-2019  |  27-Feb-2020

T4Q Result ( EPS: -29.02, P/E: -8.65 )

Revenue | NP to SH 5,929,716  |  -1,723,271
RPS | P/RPS 99.86 Cent  |  2.51
EPS | P/E | EY -29.02 Cent  |  -8.65  |  -11.56%
DPS | DY | Payout % 19.04 Cent  |  7.59%  |  - %
NAPS | P/NAPS 2.58  |  0.97
QoQ | YoY   -183.53%  |    -194.91%
NP Margin | ROE -30.71%  |  -11.25%
F.Y. | Ann. Date 30-Sep-2020  |  26-Nov-2020

Annualized Result ( EPS: -45.42, P/E: -5.53 )

Revenue | NP to SH 4,650,268  |  -2,697,352
RPS | P/RPS 78.31 Cent  |  3.21
EPS | P/E | EY -45.42 Cent  |  -5.53  |  -18.10%
DPS | DY | Payout % -
NAPS | P/NAPS -
QoQ | YoY   -2.30%  |    -284.65%
NP Margin | ROE -60.31%  |  -17.61%
F.Y. | Ann. Date 30-Sep-2020  |  26-Nov-2020


Hints :
Click the QoQ or YoY on table to view the QoQ or YoY Financial Result page.

Click here to modify the Visible Columns.

Date Financial Result Financial Ratio Per Share Item Performance Valuation (End of Quarter) Valuation (Ann. Date)
F.Y. Ann. Date Quarter # Revenue PBT NP NP to SH Div Net Worth Div Payout % NP Margin ROE NOSH RPS Adj. RPS EPS Adj. EPS DPS Adj. DPS NAPS Adj. NAPS QoQ YoY EOQ Date EOQ Price EOQ P/RPS EOQ P/EPS EOQ P/NAPS EOQ EY EOQ DY ANN Date ANN Price ANN P/RPS ANN P/EPS ANN P/NAPS ANN EY ANN DY
31-Dec-2020 26-Nov-2020 30-Sep-2020 3 5,929,716 -1,565,562 -1,821,127 -1,723,271 1,130,705 15,320,269 - % -30.71% -11.25% 5,653,236 104.89 99.86 -30.48 -29.02 20.00 19.04 2.7100 2.58   -183.53%   -194.91% 30-Sep-2020 2.08 1.98 -6.82 0.77 -14.66% 9.62% 26-Nov-2020 2.60 2.48 -8.53 0.96 -11.72% 7.69%
31-Dec-2020 27-Aug-2020 30-Jun-2020 2 7,140,634 -760,610 -701,110 -607,796 1,130,705 16,507,449 - % -9.82% -3.68% 5,653,236 126.31 120.25 -10.75 -10.24 20.00 19.04 2.9200 2.78   -185.71%   -584.76% 30-Jun-2020 2.53 2.00 -23.53 0.87 -4.25% 7.91% 27-Aug-2020 2.23 1.77 -20.74 0.76 -4.82% 8.97%
31-Dec-2020 21-May-2020 31-Mar-2020 1 9,627,226 760,125 625,184 709,107 1,131,104 17,864,226 159.51% 6.49% 3.97% 5,653,236 170.30 162.13 12.54 11.94 20.00 19.05 3.1600 3.01   -49.18%   747.37% 31-Mar-2020 2.01 1.18 16.02 0.64 6.24% 9.95% 21-May-2020 2.36 1.39 18.81 0.75 5.31% 8.47%
31-Dec-2019 27-Feb-2020 31-Dec-2019 4 10,406,938 1,489,406 1,332,246 1,395,353 1,131,104 18,487,432 81.06% 12.80% 7.55% 5,653,649 184.07 175.26 24.68 23.50 20.00 19.05 3.2700 3.11   -23.15%   7,223.51% 31-Dec-2019 3.29 1.79 13.33 1.01 7.50% 6.08% 27-Feb-2020 2.93 1.59 11.87 0.90 8.42% 6.83%
31-Dec-2019 28-Nov-2019 30-Sep-2019 3 10,471,963 1,602,956 1,755,422 1,815,749 1,074,639 18,224,797 59.18% 16.76% 9.96% 5,659,875 185.02 176.35 32.08 30.58 19.00 18.10 3.2200 3.07   2,145.68%   725.39% 30-Sep-2019 3.03 1.64 9.44 0.94 10.59% 6.27% 28-Nov-2019 3.11 1.68 9.69 0.97 10.32% 6.11%
31-Dec-2019 29-Aug-2019 30-Jun-2019 2 10,443,065 -107,771 -150,423 -88,760 1,074,639 18,055,071 - % -1.44% -0.49% 5,659,897 184.51 175.87 -1.57 -1.49 19.00 18.10 3.1900 3.04   18.97%   -106.35% 28-Jun-2019 3.24 1.76 -206.60 1.02 -0.48% 5.86% 29-Aug-2019 3.12 1.69 -198.95 0.98 -0.50% 6.09%
31-Dec-2019 23-May-2019 31-Mar-2019 1 10,263,689 -118,887 -175,273 -109,536 1,074,556 17,882,664 - % -1.71% -0.61% 5,659,071 181.37 172.85 -1.94 -1.84 19.00 18.10 3.1600 3.01   -459.20%   -109.17% 29-Mar-2019 3.20 1.76 -165.32 1.01 -0.60% 5.94% 23-May-2019 3.13 1.73 -161.71 0.99 -0.62% 6.07%
31-Dec-2018 27-Feb-2019 31-Dec-2018 4 9,927,607 -4,006 -86,353 -19,588 1,074,556 18,206,508 - % -0.87% -0.11% 5,654,195 175.58 167.19 -0.35 -0.33 19.00 18.10 3.2200 3.07   93.25%   -101.69% 31-Dec-2018 3.02 1.72 -871.74 0.94 -0.11% 6.29% 27-Feb-2019 3.47 1.98 -1,001.64 1.08 -0.10% 5.48%
31-Dec-2018 30-Nov-2018 30-Sep-2018 3 9,964,575 72,904 -361,421 -290,340 397,931 17,535,512 - % -3.63% -1.66% 5,656,617 176.16 167.81 -5.13 -4.89 7.03 6.70 3.1000 2.95   -120.79%   -112.11% 28-Sep-2018 4.99 2.83 -97.22 1.61 -1.03% 1.41% 30-Nov-2018 2.86 1.62 -55.72 0.92 -1.79% 2.46%
31-Dec-2018 29-Aug-2018 30-Jun-2018 2 9,634,932 1,589,785 1,322,908 1,396,702 397,931 19,069,225 28.49% 13.73% 7.32% 5,658,524 170.27 162.26 24.68 23.52 7.03 6.70 3.3700 3.21   16.94%   -49.38% 29-Jun-2018 4.88 2.87 19.77 1.45 5.06% 1.44% 29-Aug-2018 5.16 3.03 20.90 1.53 4.78% 1.36%
31-Dec-2018 24-May-2018 31-Mar-2018 1 9,504,389 1,371,445 1,118,218 1,194,419 284,944 18,888,958 23.86% 11.77% 6.32% 5,655,377 168.06 160.06 21.12 20.11 5.04 4.80 3.3400 3.18   2.99%   -60.74% 30-Mar-2018 4.90 2.92 23.20 1.47 4.31% 1.03% 24-May-2018 4.93 2.93 23.34 1.48 4.28% 1.02%
31-Dec-2017 27-Feb-2018 31-Dec-2017 4 9,328,709 1,318,258 1,071,038 1,159,697 284,944 1,532,409 24.57% 11.48% 75.68% 449,387 2,075.87 157.10 258.06 19.53 63.41 4.80 3.4100 0.26   -51.61%   -59.73% 29-Dec-2017 5.63 0.27 2.18 1.65 45.84% 11.26% 27-Feb-2018 5.27 0.25 2.04 1.55 48.97% 12.03%
31-Dec-2017 23-Nov-2017 30-Sep-2017 3 9,067,642 2,637,704 2,299,864 2,396,644 990,223 19,285,249 41.32% 25.36% 12.43% 5,672,132 159.86 152.70 42.25 40.36 17.46 16.68 3.4000 3.25   -13.13%   56.41% 29-Sep-2017 5.38 3.37 12.73 1.58 7.85% 3.24% 23-Nov-2017 5.10 3.19 12.07 1.50 8.28% 3.42%
31-Dec-2017 24-Aug-2017 30-Jun-2017 2 8,998,059 2,907,536 2,659,763 2,759,005 990,223 19,311,222 35.89% 29.56% 14.29% 5,663,115 158.89 151.53 48.72 46.46 17.49 16.68 3.4100 3.25   -9.32%   111.76% 30-Jun-2017 5.50 3.46 11.29 1.61 8.86% 3.18% 24-Aug-2017 6.05 3.81 12.42 1.77 8.05% 2.89%
31-Dec-2017 29-May-2017 31-Mar-2017 1 8,941,481 3,173,202 2,951,852 3,042,426 933,452 20,664,379 30.68% 33.01% 14.72% 5,938,040 150.58 150.58 51.24 51.24 15.72 15.72 3.4800 3.48   5.64%   187.74% 31-Mar-2017 5.45 3.62 10.64 1.57 9.40% 2.88% 29-May-2017 6.11 4.06 11.93 1.76 8.39% 2.57%
31-Dec-2016 23-Feb-2017 31-Dec-2016 4 8,931,617 3,090,592 2,800,697 2,880,078 933,452 19,856,161 32.41% 31.36% 14.50% 5,657,026 157.89 150.41 50.91 48.50 16.50 15.72 3.5100 3.34   87.96%   128.96% 30-Dec-2016 4.58 2.90 9.00 1.30 11.12% 3.60% 23-Feb-2017 5.47 3.46 10.74 1.56 9.31% 3.02%
31-Dec-2016 24-Nov-2016 30-Sep-2016 3 8,940,555 1,651,671 1,487,557 1,532,302 412,792 18,689,041 26.94% 16.64% 8.20% 5,663,346 157.87 150.56 27.06 25.80 7.30 6.95 3.3000 3.15   17.61%   24.66% 30-Sep-2016 4.55 2.88 16.82 1.38 5.95% 1.60% 24-Nov-2016 4.63 2.93 17.11 1.40 5.84% 1.58%
31-Dec-2016 25-Aug-2016 30-Jun-2016 2 8,768,524 1,557,706 1,270,842 1,302,866 412,792 18,220,304 31.68% 14.49% 7.15% 5,658,479 154.96 147.67 23.03 21.94 7.30 6.95 3.2200 3.07   23.22%   11.45% 30-Jun-2016 4.45 2.87 19.33 1.38 5.17% 1.64% 25-Aug-2016 4.30 2.77 18.68 1.34 5.35% 1.70%
31-Dec-2016 24-May-2016 31-Mar-2016 1 8,517,120 1,316,851 1,028,873 1,057,342 401,902 17,964,443 38.01% 12.08% 5.89% 5,649,196 150.77 143.43 18.72 17.81 7.10 6.77 3.1800 3.03   -15.94%   -11.33% 31-Mar-2016 4.54 3.01 24.26 1.43 4.12% 1.56% 24-May-2016 4.25 2.82 22.71 1.34 4.40% 1.67%
31-Dec-2015 23-Feb-2016 31-Dec-2015 4 8,395,906 1,529,967 1,242,999 1,257,877 401,902 19,047,420 31.95% 14.80% 6.60% 5,652,053 148.55 141.39 22.26 21.18 7.10 6.77 3.3700 3.21   2.34%   5.82% 31-Dec-2015 4.38 2.95 19.68 1.30 5.08% 1.62% 23-Feb-2016 4.36 2.94 19.59 1.29 5.10% 1.63%
31-Dec-2015 26-Nov-2015 30-Sep-2015 3 8,161,995 1,540,547 1,190,820 1,229,158 357,478 19,090,639 29.08% 14.59% 6.44% 5,664,878 144.08 137.45 21.70 20.70 6.30 6.02 3.3700 3.21   5.15%   -3.92% 30-Sep-2015 4.15 2.88 19.13 1.23 5.23% 1.52% 26-Nov-2015 4.31 2.99 19.86 1.28 5.03% 1.46%
31-Dec-2015 26-Aug-2015 30-Jun-2015 2 8,368,857 1,488,973 1,129,293 1,168,977 357,478 17,475,025 30.58% 13.49% 6.69% 5,673,709 147.50 140.94 20.60 19.69 6.30 6.02 3.0800 2.94   -1.97%   -12.49% 30-Jun-2015 4.20 2.85 20.38 1.36 4.91% 1.50% 26-Aug-2015 3.91 2.65 18.98 1.27 5.27% 1.61%
31-Dec-2015 28-May-2015 31-Mar-2015 1 8,296,523 1,536,507 1,148,848 1,192,490 368,614 17,226,761 30.91% 13.85% 6.92% 5,666,698 146.41 139.72 21.04 20.08 6.50 6.21 3.0400 2.90   0.32%   -22.66% 31-Mar-2015 4.23 2.89 20.10 1.39 4.97% 1.54% 28-May-2015 4.26 2.91 20.24 1.40 4.94% 1.53%
31-Dec-2014 26-Feb-2015 31-Dec-2014 4 8,229,433 1,524,506 1,140,286 1,188,677 368,614 16,343,156 31.01% 13.86% 7.27% 5,674,706 145.02 138.59 20.95 20.02 6.50 6.21 2.8800 2.75   -7.09%   -25.85% 31-Dec-2014 4.07 2.81 19.43 1.41 5.15% 1.60% 26-Feb-2015 4.11 2.83 19.62 1.43 5.10% 1.58%
31-Dec-2014 21-Nov-2014 30-Sep-2014 3 8,291,588 1,594,130 1,238,331 1,279,353 391,247 15,603,816 30.58% 14.93% 8.20% 5,674,115 146.13 139.64 22.55 21.55 6.90 6.59 2.7500 2.63   -4.23%   -22.38% 30-Sep-2014 4.18 2.86 18.54 1.52 5.39% 1.65% 21-Nov-2014 4.08 2.79 18.10 1.48 5.53% 1.69%
31-Dec-2014 28-Aug-2014 30-Jun-2014 2 8,177,996 1,585,661 1,301,847 1,335,854 391,247 15,583,313 29.29% 15.92% 8.57% 5,666,659 144.32 137.72 23.57 22.50 6.90 6.59 2.7500 2.62   -13.36%   -11.88% 30-Jun-2014 4.20 2.91 17.82 1.53 5.61% 1.64% 28-Aug-2014 4.65 3.22 19.73 1.69 5.07% 1.48%
31-Dec-2014 29-May-2014 31-Mar-2014 1 8,491,593 1,836,896 1,516,029 1,541,827 465,058 15,703,488 30.16% 17.85% 9.82% 5,669,129 149.79 143.00 27.20 25.97 8.20 7.83 2.7700 2.64   -3.82%   -0.61% 31-Mar-2014 4.20 2.80 15.44 1.52 6.48% 1.95% 29-May-2014 4.22 2.82 15.52 1.52 6.44% 1.94%
31-Dec-2013 27-Feb-2014 31-Dec-2013 4 8,327,537 1,766,493 1,584,051 1,602,995 465,058 15,487,336 29.01% 19.02% 10.35% 5,673,017 146.79 140.24 28.26 27.00 8.20 7.83 2.7300 2.61   -2.74%   14.30% 31-Dec-2013 4.38 2.98 15.50 1.60 6.45% 1.87% 27-Feb-2014 4.31 2.94 15.25 1.58 6.56% 1.90%
31-Dec-2013 28-Nov-2013 30-Sep-2013 3 8,133,920 1,847,414 1,637,869 1,648,170 527,328 14,514,929 31.99% 20.14% 11.35% 5,669,894 143.46 136.98 29.07 27.76 9.30 8.88 2.5600 2.44   8.73%   26.19% 30-Sep-2013 4.22 2.94 14.52 1.65 6.89% 2.20% 28-Nov-2013 4.28 2.98 14.72 1.67 6.79% 2.17%
31-Dec-2013 29-Aug-2013 30-Jun-2013 2 7,956,040 1,762,982 1,510,787 1,515,900 527,328 14,571,963 34.79% 18.99% 10.40% 5,670,024 140.32 133.98 26.74 25.53 9.30 8.88 2.5700 2.45   -2.28%   3.62% 28-Jun-2013 3.89 2.77 14.55 1.51 6.87% 2.39% 29-Aug-2013 4.04 2.88 15.11 1.57 6.62% 2.30%
31-Dec-2013 30-May-2013 31-Mar-2013 1 7,851,058 1,831,517 1,549,554 1,551,294 498,836 14,019,740 32.16% 19.74% 11.07% 5,676,008 138.32 132.22 27.33 26.12 8.80 8.40 2.4700 2.36   10.61%   21.12% 29-Mar-2013 3.62 2.62 13.25 1.47 7.55% 2.43% 30-May-2013 3.90 2.82 14.27 1.58 7.01% 2.26%
31-Dec-2012 28-Feb-2013 31-Dec-2012 4 7,892,865 1,817,230 1,402,501 1,402,501 498,836 13,155,225 35.57% 17.77% 10.66% 5,670,356 139.20 132.92 24.73 23.62 8.80 8.40 2.3200 2.22   7.38%   -1.78% 31-Dec-2012 3.55 2.55 14.35 1.53 6.97% 2.48% 28-Feb-2013 3.70 2.66 14.96 1.59 6.68% 2.38%
31-Dec-2012 29-Nov-2012 30-Sep-2012 3 8,297,604 1,751,993 1,306,092 1,306,092 487,044 12,576,498 37.29% 15.74% 10.39% 5,665,089 146.47 139.74 23.06 22.00 8.60 8.20 2.2200 2.12   -10.72%   -9.34% 28-Sep-2012 3.50 2.39 15.18 1.58 6.59% 2.46% 29-Nov-2012 3.50 2.39 15.18 1.58 6.59% 2.46%
31-Dec-2012 29-Aug-2012 30-Jun-2012 2 8,670,364 1,933,862 1,462,890 1,462,890 487,044 12,805,805 33.29% 16.87% 11.42% 5,666,285 153.02 146.01 25.82 24.64 8.60 8.20 2.2600 2.16   14.21%   2.30% 29-Jun-2012 3.60 2.35 13.94 1.59 7.17% 2.39% 29-Aug-2012 3.30 2.16 12.78 1.46 7.82% 2.61%
31-Dec-2012 30-May-2012 31-Mar-2012 1 8,446,907 1,725,701 1,280,843 1,280,843 486,935 12,627,211 38.02% 15.16% 10.14% 5,662,426 149.17 142.25 22.62 21.57 8.60 8.20 2.2300 2.13   -10.30%   -9.92% 30-Mar-2012 3.92 2.63 17.33 1.76 5.77% 2.19% 30-May-2012 3.84 2.57 16.98 1.72 5.89% 2.24%
31-Dec-2011 28-Feb-2012 31-Dec-2011 4 8,493,686 1,900,648 1,427,877 1,427,877 486,935 11,944,616 34.10% 16.81% 11.95% 5,660,956 150.04 143.04 25.22 24.05 8.60 8.20 2.1100 2.01   -0.89%   11.85% 30-Dec-2011 3.83 2.55 15.18 1.82 6.59% 2.25% 28-Feb-2012 3.80 2.53 15.07 1.80 6.64% 2.26%
31-Dec-2011 24-Nov-2011 30-Sep-2011 3 7,720,966 1,950,132 1,440,721 1,440,721 464,560 11,665,883 32.24% 18.66% 12.35% 5,663,050 136.34 130.03 25.44 24.26 8.20 7.82 2.0600 1.96   0.75%   13.19% 30-Sep-2011 3.51 2.57 13.80 1.70 7.25% 2.34% 24-Nov-2011 3.86 2.83 15.17 1.87 6.59% 2.12%
31-Dec-2011 25-Aug-2011 30-Jun-2011 2 6,608,046 1,903,310 1,429,993 1,429,993 464,560 11,666,627 32.49% 21.64% 12.26% 5,663,411 116.68 111.28 25.25 24.08 8.20 7.82 2.0600 1.96   0.57%   10.35% 30-Jun-2011 3.60 3.09 14.26 1.75 7.01% 2.28% 25-Aug-2011 3.41 2.92 13.51 1.66 7.40% 2.40%
31-Dec-2011 26-May-2011 31-Mar-2011 1 5,938,513 1,887,098 1,421,776 1,421,930 454,664 11,675,140 31.98% 23.94% 12.18% 5,667,544 104.78 100.01 25.09 23.95 8.00 7.66 2.0600 1.97   11.38%   7.67% 31-Mar-2011 3.68 3.51 14.67 1.79 6.82% 2.17% 26-May-2011 3.52 3.36 14.03 1.71 7.13% 2.27%
31-Dec-2010 23-Feb-2011 31-Dec-2010 4 5,333,103 1,731,452 1,276,340 1,276,596 454,664 11,617,468 35.62% 23.93% 10.99% 5,667,058 94.11 89.81 22.53 21.50 8.00 7.66 2.0500 1.96   0.30%   -3.56% 30-Dec-2010 3.39 3.60 15.05 1.65 6.65% 2.36% 23-Feb-2011 3.31 3.52 14.69 1.61 6.81% 2.42%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.


NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ Δ & YoY Δ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.


Trade this stock and win a FREE I3investor T-shirt after 5 trades. Find out more.
  25 people like this.
 
mydear amy LAOSAI!!!!
30/11/2020 5:04 PM
Bearimu What happened to GENM? 4.50pm??????!!!!!!!! Any one please give us a professional reply.
30/11/2020 5:05 PM
padanggrus 等下就有几条sohai出来叫你们放心买 ,
2.67就出现一下下 ,
2.5死一堆人,
2.48以为很低,
结果今天给你2.45!
30/11/2020 5:13 PM
Bearimu Any platforms to get latest news or insights for trading as I am still new in this. Appreciate all the sifus to pass me some insights! Much love!!!
30/11/2020 5:31 PM
JBond007 It happen on all the blue chips.....It's 30 Nov, probably some institution fund close their account. If you were in the buying queue for the deep blue (Maybank, PBB, Tenaga) just now, maybe it's a durian runtuh for you.
30/11/2020 5:31 PM
LA777 Nothing much to worry.
30/11/2020 5:34 PM
William Ng JBond007, can u please explain more about this? because today most of the bank drop 4~6%!!!
30/11/2020 6:09 PM
JBond007 @William Ng......maybe rebalancing on the MSCI Index,.....please refer to the Star.
https://www.thestar.com.my/business/business-news/2020/11/30/klci-slumps-over-40-points-in-regional-sell-off
30/11/2020 6:33 PM
mita29 big fund/FF pushed up with retail on vaccine news now they wanna be the first to run away with $$.

"The sharp decline was in line with the performance of its regional peers, as foreign funds sold down on equities following the recent rally."

Goldman Sachs:"TERIMA KASIH TO THE 90% of RETAIL INVESTORs"
https://markets.businessinsider.com/news/stocks/goldman-traders-made-hundred-millions-days-first-quarter-volatility-gains-2020-5-1029155649
30/11/2020 6:42 PM
JBond007 @mita29...lousy investigation, your info from Jho Low kah? Goldman Sachs just paid us $3B over 1MDB corruption scandal. Private eye job is not suitable for you, please continue your tourism promotion work.
mita = Malaysian Inbound Tourism Association
mita = Malaysian Inbound Tourism Association
mita = Malaysian Inbound Tourism Association
30/11/2020 6:58 PM
Goldgent 放心吧! 刚与玲珑小镇巴登古鲁村长通电话,他叫大家放心买。
他叮嘱大家斯文点, 不要在社交媒体上讲粗话。
30/11/2020 7:23 PM
choysun @JBond007 You managed to get durian runtuh? :p
30/11/2020 7:26 PM
JBond007 @choysun...few lots Genting & GenM at closing price. Hope it's the Musang King.
30/11/2020 7:37 PM
Jason85 Still waiting GenM break 2.0... Waiting for so long haha
30/11/2020 7:45 PM
choysun I hope it will turn out to be Blackthorn for you. More premium! Hahaha
30/11/2020 7:51 PM
haha135 TP 1
30/11/2020 8:25 PM
emsvsi The last minute share price move must be compared to the drops in Banks, Utilities, Petrochemical and Telecoms then it becomes clear which was better

Sincerely,
EMSVSI
30/11/2020 8:56 PM
emsvsi Moderna Submits Covid-19 Vaccine For Emergency Approval, Says It Is 100% Effective At Preventing Severe Forms Of Disease

Nov 30, 2020,07:00am EST

TOPLINE Moderna will submit its Covid-19 vaccine for emergency use approval in the U.S. Monday after new trial data showed it to be 94% effective at preventing the disease, findings that are consistent with earlier data from the Phase 3 clinical trial.

New findings from the Phase 3 clinical trial, which involved over 30,000 participants, showed the vaccine to be 100% effective at preventing severe Covid-19 and 94% at preventing the disease more broadly.

https://www.forbes.com/sites/roberthart/2020/11/30/moderna-submits-covid-19-vaccine-for-emergency-approval-says-it-is-100-effective-at-preventing-severe-forms-of-disease/?sh=6dc931345f56
30/11/2020 9:02 PM
mydear amy So many stupid ppl keep relate vaccine with GENM.
30/11/2020 9:09 PM
choysun @emsvsi Fantastic news! Thanks for sharing! :)
30/11/2020 9:13 PM
choysun @mydear amy Vaccine news is good news to all recovery play la. Celebrate the news, its great for mankind! :)
30/11/2020 9:14 PM
mita29 Very good, 185 cases in placebo vs 11 cases in vaccine group (30K sample size). 30 severe cases in placebo and 0/11 case in vaccine group. if we have 3 million ppl participating in this vaccine trial, we would have ~1100 cases in the vaccine group, doubt we would still get 0 severe case (100% prevention). Anyways Moderna trial is so much better than pfizer trial because it include elders and young ppl with chronic disease. Bottom line is the moderna vaccine is effective in fighting covid even for the elders. Now we need to know the duration of protection so that government can develop an effective vaccine program. Tomolo pump or sell on vaccine news? GUESS?
30/11/2020 10:13 PM
padanggrus 讲粗口 的确 是不斯文
但是有些斯斯文文的 的确 讲骗话

你什么时候和我村长通电话
我村长什么时候叫大家放心买 !

你可能也是玲珑人
做事 光民正大 ,回去还是有颜面
面对· 江东父老!

不要在这里骂架 ,
在这里怼糕那些老千就好

小弟受教了!
30/11/2020 10:25 PM
mita29 and why our government so quick to buy from pzifer and not from moderna? Pfizer got political connection? ADUIiiiiiiiiiiiiiiiiiiiii
30/11/2020 10:30 PM
choysun @mita29 Doubt we will only acquire one vaccine type. Look at the other countries, they ordered from multiple companies. I'm keen to see how the China ones play out when they complete their big trials.
30/11/2020 10:52 PM
mita29 Good! i prefer China one because they use tried and tested technique (eg inactivated virus) with great long term safety record. MRNA vaccine has never been approved to use on human before!!! I don't want to become mutant or zombie after 3 years of using it. Mita very scared
30/11/2020 11:12 PM
choysun @mita29 It could also be an absolute breakthrough that open doors for many medical first to come! :)
01/12/2020 12:08 AM
mita29 Are you guys ready for goose egg size arm? Lets do it to fight COVID!! Let me convince my old dad this is absolutely fine!!!

"This summer, computational biologist Luke Hutchison volunteered for a trial of Moderna's COVID-19 vaccine. But after the second injection, his arm swelled up to the size of a “goose egg"

"This is higher reactogenicity than is ordinarily seen with most flu vaccines, even the high-dose ones"

https://science.sciencemag.org/content/370/6520/1022
01/12/2020 12:12 AM
mita29 Ok just give me the CHINA one. Any government official if you are reading this, can we have China vaccine too?
01/12/2020 12:14 AM
JBond007 @mita29.....ayoyo, why whole night talked about vaccine? Any intention to change ID 'mita29' to 'vaccine29'?
01/12/2020 12:30 AM
Goldgent @padanggrus...啊,弄错了,不是村长,是玲珑小镇巴登古鲁的股王。
01/12/2020 12:32 AM
mita29 I only made 4 posts tonight on GEMN, other vaccine hype promoters spam 90%-100% efficacy news on all their invested counters like million times without knowing what it actually means. Mita is still mita
01/12/2020 12:50 AM
Jonny8855 https://www.mysanantonio.com/business/article/In-the-Next-Few-Days-Pfizer-Could-Start-Mass-15764097.php
01/12/2020 7:47 AM
Jonny8855 https://www.google.com/amp/s/www.foxbusiness.com/markets/two-coronavirus-vaccines-available-in-coming-weeks-azar.amp
01/12/2020 7:54 AM
Alfonso genting is so strong, even in cmco still survive, goodjob genting! i am looking forward to your Rm6 in 4 years time!
01/12/2020 10:10 AM
SonOfaGun Wow. You're really a long term investor. Malaysian Warren buffet. Everyday jiak buffet. Haha
01/12/2020 10:16 AM
choysun Who got cheap tickets this morning? :p
01/12/2020 10:30 AM
choysun Looks like Moderna vaccine is really good. Moderna up 20.24% yesterday as well. Crazy! Don't complain I share vaccine news ya :p
https://www.sciencemag.org/news/2020/11/absolutely-remarkable-no-one-who-got-modernas-vaccine-trial-developed-severe-covid-19
01/12/2020 11:07 AM
kaitan mRNA vaccines are DNA altering. Don't take them. The China ones may not be mRNA, have to see.
01/12/2020 11:55 AM
choysun @kaitan mRNA does not alter your DNA la. I'm looking forward to the advancement to medical science!
01/12/2020 12:43 PM
mita29 A very smart & knowledgeable person wrote the following article.

Managing expectations for COVID-19 vaccine.
https://www.thejakartapost.com/academia/2020/11/30/managing-expectations-for-covid-19-vaccine.html

Some key points from the article that will make our vaccine program successful
1) Free for all or heavily subsidized vaccine (Thank you glove companies but we will probably need more from your record net profit HEHEHHEEH )

2) Focus on a vaccine (if any) with evidence to prevent/reduce transmission.

3) Aim to vaccinate 80% or more of our population to achieve herd immunity.
01/12/2020 1:17 PM
mita29 Oh the writer's credential, no wonder lah from Havard
https://ash.harvard.edu/people/panji-hadisoemarto
01/12/2020 1:21 PM
emsvsi The mRNA-based vaccines are ground-breaking medical technology

Those people who think they alter DNA reminds me of the self-proclaimed 'new-age' anti-vaccine or anti-vaxxers

You are standing today because your parents and the Malaysian government made it mandatory for everyone to be vaccinated

Perhaps the vaccines were wasted on you
01/12/2020 1:29 PM
kaitan they do alter DNA. Do your research. Previous vaccines were not DNA based. Perhaps they were wasted on you @emsvi . How old are you, you patronising ass.
01/12/2020 2:13 PM
newbie128 instead of vaccine news, what are the oods genting will do reversal on impairment and tax expenses on future QRs. Heheheeh, super profit cycle coming up soon, but not so soon also la
01/12/2020 2:41 PM
kaitan https://www.bitchute.com/video/8TzX7lBvuyT9/
01/12/2020 2:44 PM
mita29 No lah don't scare ppl kaitan XDDD
mRNA covid vaccine from Pzifer/Mordena will not edit your DNA, Its used as just an instruction for our body to make protein (eg Spike protein from covid)..

https://www.youtube.com/watch?v=gG7uCskUOrA

Don't worry you will not become zombie.
01/12/2020 3:39 PM
choysun All aboard before vaccine approval!!!! HUAT AH! :)
01/12/2020 4:32 PM
JBond007 Wah.....so serene, peaceful & tranquil...deep pocket uncles sitting in Genting Highlands minum kopi discussing vaccine scientific research.
01/12/2020 4:44 PM
JBond007 Wondered you'll can view the Klang rubber factory inferno from the hilltop or not?
01/12/2020 4:53 PM